SPS
ORIC icon

Susquehanna Portfolio Strategies’s Oric Pharmaceuticals ORIC Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$144K Buy
+11,373
New +$129K ﹤0.01% 921
2025
Q4 		– Sell
-27,524
Closed -$330K – 1087
2025
Q3 		$330K Buy
+27,524
New +$290K 0.01% 914

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Susquehanna Portfolio Strategies's ORIC Position: Q1 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Oric Pharmaceuticals (ORIC) in Q1 2026: 11,373 shares worth $144K. The stake represents ﹤0.01% of the portfolio and ranks #921 among its holdings. This is a return to the name: Susquehanna Portfolio Strategies previously reported a position in ORIC as recently as Q3 2025.

Susquehanna Portfolio Strategies first reported a position in ORIC in Q3 2025 and has held it in 2 quarters since. The position peaked at $330K in Q3 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Susquehanna Portfolio Strategies held 11,373 shares of Oric Pharmaceuticals worth $144K as of Q1 2026.
  • Oric Pharmaceuticals was a new Susquehanna Portfolio Strategies position in Q1 2026.
  • Oric Pharmaceuticals made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #921 holding.
  • Susquehanna Portfolio Strategies first reported a position in Oric Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • Susquehanna Portfolio Strategies's Oric Pharmaceuticals position peaked at $330K in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.